Cyxone AB (publ) (STO:CYXO)
Sweden
· Delayed Price · Currency is SEK 0.0180
0.00 (0.00%)
Inactive · Last trade price
on Dec 5, 2024
Cyxone AB Company Description
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases.
Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial.
The company was founded in 2015 and is headquartered in Malmö, Sweden.
Cyxone AB (publ)
| Country | Sweden |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Kjell Stenberg |
Contact Details
Address: Hylle Boulevard 34 Malmö, 215 32 Sweden | |
| Phone | 46 7 08 88 21 72 |
| Website | cyxone.com |
Stock Details
| Ticker Symbol | CYXO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007815428 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kjell G. Stenberg Ph.D. | Chief Executive Officer |
| Malin Lindskog | Chief Financial Officer - On Leave |